# The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis

> **NCT07013838** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Chinese SLE Treatment And Research Group** · enrollment: 50 (estimated)

## Conditions studied

- Takayasu Arteritis (TAK)

## Interventions

- **DRUG:** Deucravacitinib
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT07013838
- **Lead sponsor:** Chinese SLE Treatment And Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07013838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07013838, "The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT07013838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*